Clinical Trial Update: To Compare Efficacy and Safety of CT-P16 and European Union-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing CT-P16, a bevacizumab biosimilar from Celltrion, with EU-approved Avastin in first-line treatment of metastatic or recurrent non-squamou…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Avastin (bevacizumab)
• CT-P16

Snippet

Sponsor: Celltrion | Conditions: Adenocarcinoma of Lung | Phase 3 | Status: COMPLETED | Results posted: 2025-03-17